Carregant...
Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function
PURPOSE: Dual blockade of HER2 with trastuzumab with lapatinib or with pertuzumab is a superior treatment approach compared to single agent HER2 inhibitors. However, many HER2-overexpressing breast cancers still escape from this combinatorial approach. Inhibition of HER2 and downstream phosphatidyli...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3563762/ https://ncbi.nlm.nih.gov/pubmed/23224399 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2024 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|